Notably, mutations in the genes encoding isocitrate dehydrogenase (IDH)-1 and IDH-2 have been described in 5% of de novo GBM and more than 90% of secondary GBM [review in (81)]. The gene discussed is IDH3A; the disease is glioblastoma.